DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

2020
INDEX
Diuretics (Cont.):
inhibitors of Na + -CI − symport, 678t,
686–690, 688t
inhibitors of Na + -K + -2CI − symport,
678t, 682–686, 683t
inhibitors of nonspecific cation
channel, 695–696
inhibitors of renal epithelial sodium
channels, 678t, 690–692,
690t
intolerance, 701
loop (See Loop diuretics)
mechanism of action of, 697f
and organic acid and organic base
secretion, 676, 676f
osmotic (See Osmotic diuretics)
polymorphisms and response to,
160t
potassium-sparing, 690–692, 690t
as antihypertensive agents, 774t,
778
chemistry of, 690, 690t
drug interactions with, 691–692
excretory and renal hemodynamic
effects of, 678t, 691
mechanism of action of, 690–691,
691f
pharmacology of, 690t
and renal hemodynamics, 691
site of action of, 690–691
structure of, 690t
therapeutic uses of, 692
toxicity, adverse effects, and
contraindications to,
691–692
and urinary excretion, 691
renal epithelial transport and,
674–676
renal handling of specific anions and
cations and, 676–677
resistance (edema refractory to),
699
role in clinical medicine, 698–701
site of action of, 697f
therapeutic uses of, Brater’s
algorithm for, 699, 700f
thiazide (See Thiazide diuretics)
thiazide, SLC transporters and, 102t
DIURIL (chlorothiazide), 688t, 791
Diversity, ethnic, 150–151
DIVIGEL (estradiol), 1839t
DMPP. See
Dimethylphenylpiperazinium
(DMPP)
DNA methylation, 97
Dobutamine
adrenergic receptors and, 206t
adverse effects of, 290, 321t
cardiovascular effects of, 290
pharmacological properties of, 321t
structure of, 279t
therapeutic uses of, 290, 321t
for heart failure, 804–805
Docetaxel, 1668t–1670t
pharmacokinetics of, 1832t
Docosanol, 1596t, 1604
for cutaneous viral infections, 1818
Docusate, 1330t
Dofetilide, 839
adverse effects of, 839
arrhythmias caused by, 821t
contraindications to, 833t
dosage and administration of, 835t
electrophysiological actions of, 829t
mechanism of action of, 830
pharmacokinetics of, 835t, 839
structure of, 839
Dolasetron, arrhythmias caused by,
832
Domperidone, 1326
Donepezil
for Alzheimer’s, 253
pharmacokinetics of, 1833t
structure of, 243f
Donor cell chimerism, 1021
Dopa, in catecholamine synthesis, 194f
DOPAC. See 3,4-dihydroxyphenyl
acetic acid (DOPAC)
Dopa decarboxylase, 195
Dopamine
therapeutic uses of, for heart failure,
804
and vasopressin secretion, 704
Dopamine beta-hydroxylase (DβH),
194, 195
Dopamine beta-hydroxylase
deficiency, 195
Dopamine (DA)
addiction and, 357
antipsychotics and, 427t
in behavior, 356–357
cardiovascular effects of, 288
catecholamine release and, 355
in central nervous system, 382
central nervous system and,
355–356
chemistry, 351
cognition and, 357
heart and, 355
history of, 351
Dopamine (DA) (Cont.):
kidneys and, 355
learning and, 357
memory and, 357
metabolism of, 351–353
Parkinson disease and, 356–357
pharmacology of, 288
physiological functions of, 353–359
pituitary gland and, 355
precautions, adverse reactions, and
contraindications to, 288
sources of, 351
structure of, 279t
synthesis of, 194–196, 351–353
therapeutic uses of, 288–289, 290
vasculature and, 355
Dopamine hypothesis, 417
Dopamine receptor(s)
agonists, 357–358, 616–617,
1114–1115
antagonists, 358–359, 1325–1326
for nausea, 1343
antipsychotics and, 427t
D 2
, 427t
Dopaminergic agonists, therapeutic
uses of, for heart failure,
804–805
Dopamine transporter, antidepressant
potencies at, 406t
Dopamine transporter (DAT), 116,
198t
polymorphisms in, 150f
DOPEG. See 3,4-dihydroxyphenyl
glycol (DOPEG)
DOPET. See 3,4-
dihydroxyphenylethanol
(DOPET)
DORAL (quazepam), 466t
Dorzolamide, 680
for ophthalmic use, 1787
Dosage regimens
design and optimization of, 34–37
individualization, 37, 1808
intermittent, interval for, 36
loading, 36–37
maintenance, 35–36
median effective, 73, 74f
median lethal, 73, 74f
Dose
calculation, in prescription writing,
1881
loading, 36–37
of neuromuscular blocking agents,
265t
Dose-dependent reactions, 75–76